Core Viewpoint - The nuclear medicine industry in China is experiencing a pivotal moment with the strategic partnership between YuanDa Pharmaceutical and IRE ELiT, enhancing the supply chain for medical-grade Ge-68/Ga-68 generators, which aligns with international standards and meets domestic regulatory requirements [1][7]. Industry Overview - The nuclear medicine sector is emerging as a new approach for cancer diagnosis and treatment, with a focus on drugs labeled with Lu-177 and Ga-68, where Ga-68 is crucial for developing next-generation PET imaging agents [2]. - The market for diagnostic and therapeutic radioactive drugs in China is projected to reach 9.3 billion yuan by 2025, growing at a compound annual growth rate (CAGR) of 22.7% to 26 billion yuan by 2030, indicating significant market potential [4]. Supply Chain Challenges - There is a current shortage in the supply of radioactive isotopes in China, primarily due to import monopolies. The short half-life of isotopes like Ga-68 necessitates a stable supply chain, making the local production of key isotopes essential for the industry's health [6]. - The collaboration with IRE ELiT aims to establish a reliable supply chain for Ga-68 generators, addressing clinical demand gaps in China [6][7]. Company Developments - YuanDa Pharmaceutical has established a comprehensive industry chain in nuclear medicine, covering research, production, sales, and regulatory qualifications, with a pipeline of 15 innovative products targeting various cancers [8][11]. - The company’s Chengdu facility, which received a Class A radiation safety license, is the world's first closed-loop platform for the entire nuclear medicine industry chain, with an investment exceeding 3 billion yuan [12]. - YuanDa's innovative product, SIR-Spheres Y-90 microspheres, has seen rapid growth, achieving nearly 500 million HKD in revenue in 2024, reflecting a year-on-year increase of over 140% [11]. Strategic Partnerships - The partnership with IRE ELiT will enable YuanDa to leverage its market capabilities to promote the registration, localization, and commercialization of Ga-68 generators in China, enhancing the availability of PET imaging technology [7][13]. - This collaboration is expected to serve as a foundation for localizing the nuclear medicine supply chain in China, improving industry resilience and safety [7][13].
强强联合！远大医药布局全球顶尖锗镓发生器 攻破关键核素原料供应壁垒